Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina da Universidade de Lisboa, 1649-028 Lisbon, Portugal.
Centro de Dermatologia, Hospital CUF Descobertas, 1998-018 Lisbon, Portugal.
Cells. 2024 Jun 3;13(11):964. doi: 10.3390/cells13110964.
Basal cell carcinomas (BCCs) and squamous cell carcinomas (SCCs) are high-incidence, non-melanoma skin cancers (NMSCs). The success of immune-targeted therapies in advanced NMSCs led us to anticipate that NMSCs harbored significant populations of tumor-infiltrating lymphocytes with potential anti-tumor activity. The main aim of this study was to characterize T cells infiltrating NMSCs. Flow cytometry and immunohistochemistry were used to assess, respectively, the proportions and densities of T cell subpopulations in BCCs (n = 118), SCCs (n = 33), and normal skin (NS, n = 30). CD8+ T cells, CD4+ T cell subsets, namely, Th1, Th2, Th17, Th9, and regulatory T cells (Tregs), CD8+ and CD4+ memory T cells, and γδ T cells were compared between NMSCs and NS samples. Remarkably, both BCCs and SCCs featured a significantly higher Th1/Th2 ratio (~four-fold) and an enrichment for Th17 cells. NMSCs also showed a significant enrichment for IFN-γ-producing CD8+T cells, and a depletion of γδ T cells. Using immunohistochemistry, NMSCs featured denser T cell infiltrates (CD4+, CD8+, and Tregs) than NS. Overall, these data favor a Th1-predominant response in BCCs and SCCs, providing support for immune-based treatments in NMSCs. Th17-mediated inflammation may play a role in the progression of NMSCs and thus become a potential therapeutic target in NMSCs.
基底细胞癌 (BCC) 和鳞状细胞癌 (SCC) 是高发的非黑色素瘤皮肤癌 (NMSC)。免疫靶向疗法在晚期 NMSC 中的成功促使我们预期 NMSC 中存在具有潜在抗肿瘤活性的大量肿瘤浸润淋巴细胞。本研究的主要目的是表征浸润 NMSC 的 T 细胞。流式细胞术和免疫组织化学分别用于评估 BCC(n=118)、SCC(n=33)和正常皮肤(NS,n=30)中 T 细胞亚群的比例和密度。比较了 NMSC 和 NS 样本之间的 CD8+T 细胞、CD4+T 细胞亚群,即 Th1、Th2、Th17、Th9 和调节性 T 细胞(Tregs)、CD8+和 CD4+记忆 T 细胞和γδ T 细胞。值得注意的是,BCC 和 SCC 均表现出明显更高的 Th1/Th2 比值(~四倍)和 Th17 细胞富集。NMSC 还表现出 IFN-γ 产生的 CD8+T 细胞显著富集和 γδ T 细胞耗竭。通过免疫组织化学,NMSC 显示出比 NS 更密集的 T 细胞浸润(CD4+、CD8+和 Tregs)。总体而言,这些数据支持 BCC 和 SCC 中以 Th1 为主的反应,为 NMSC 的免疫治疗提供了支持。Th17 介导的炎症可能在 NMSC 的进展中起作用,因此成为 NMSC 的潜在治疗靶点。